SCHEMBL943301

SCHEMBL943301

CC(=NNC(N)=S)c1cccc(Cl)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CTSL P07711 3/20 1.00
MEN1 O00255 1/20 0.73
KMT2A Q03164 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
ATM Q13315 1/20 0.66
METTL3 Q86U44 1/20 0.66
ALDH1A1 P00352 1/20 0.62
KDM4E B2RXH2 1/20 0.58
HTT P42858 1/20 0.58
CTSB P07858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13954747 0.83 CTSL (0.70) CTSLSMN1; SMN2ATMMETTL3ALDH1A1
SCHEMBL5522779 0.83 CTSL (0.70) CTSLMEN1KMT2ASMN1; SMN2ATM
SCHEMBL5519818 0.83 CTSL (0.70) CTSLATMMETTL3ALDH1A1KDM4E
SCHEMBL940737 0.83 CTSL (0.70) CTSLSMN1; SMN2ATMMETTL3ALDH1A1
SCHEMBL5522782 0.83 CTSL (0.70) CTSLMEN1KMT2ASMN1; SMN2ATM
SCHEMBL941204 0.83 CTSL (0.70) CTSLATMMETTL3ALDH1A1KDM4E
SCHEMBL17527524 0.83 CTSL (0.70) CTSLATMMETTL3ALDH1A1KDM4E
SCHEMBL8443945 0.82 CTSL (0.69) CTSLMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL10813077 0.81 CTSL (0.68) CTSLMEN1KMT2ASMN1; SMN2ATM
SCHEMBL5521050 0.81 ALDH1A1 (0.74) CTSLATMMETTL3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318782-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-11-27 US disclosed
US-20110275827-A1 Mitotic Kinesin Inhibitor FUJIFILM CORPORATION (JP) 2011-11-10 US disclosed
EP-1454903-B9 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2011-10-05 EP disclosed
EP-2327702-A1 Mitotic kinesin inhibitor Kyowa Hakko Kirin Co., Ltd. (JP) 2011-06-01 EP disclosed
US-7902234-B2 Thiadiazoline derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-03-08 US disclosed
US-20110004000-A1 Mitotic Kinesin Inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-01-06 US disclosed
US-7851635-B2 Mitotic kinesin inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-12-14 US disclosed
US-20100240716-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-09-23 US disclosed
EP-1454903-B1 Thiadiazoline derivatives for treating cancer KYOWA HAKKO KIRIN CO LTD (JP) 2010-09-08 EP disclosed
US-7759371-B2 Thiadiazoline derivative Kyowa Hakko Kinn Co., Ltd. (JP) 2010-07-20 US disclosed
CN-100484928-C thiadiazoline derivatives KYOWA HAKKO KOGYO KK FUJI PHOT (JP) 2009-05-06 CN disclosed
US-7425636-B2 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2008-09-16 US disclosed
US-20080207706-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD (JP) 2008-08-28 US disclosed
EP-1847534-A2 Thiadiazoline derivative Kyowa Hakko Kogyo Co., Ltd (JP) 2007-10-24 EP disclosed
US-20070213380-A1 Thiadiazoline derivative KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-09-13 US disclosed
US-20070155804-A1 Mitotic kinesin inhibitor KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN 2007-07-05 US disclosed
US-20060074113-A1 Thiadiazoline derivative KYOWA KIRIN CO., LTD. (JP) 2006-04-06 US disclosed
EP-1616866-A1 M-STAGE KINESIN INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-01-18 EP disclosed
CN-1617864-A thiadiazoline derivatives KYOWA HAKKO KOGYO KK (JP) 2005-05-18 CN disclosed
EP-1454903-A1 THIADIAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074113-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 CTSL 4237/4885MEN1 2153/4885KMT2A 558/4885
US-20070155804-A1 Mitotic kinesin inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885MEN1 3155/4885KMT2A 514/4885
US-20070213380-A1 Thiadiazoline derivative BRWD1, RB1, ARG2 CTSL 4237/4885MEN1 2153/4885KMT2A 558/4885
US-20110004000-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885MEN1 3155/4885KMT2A 514/4885
US-20100240716-A1 THIADIAZOLINE DERIVATIVE BRWD1, WDR82, RB1 CTSL 4395/4885MEN1 2027/4885KMT2A 665/4885
US-20080207706-A1 THIADIAZOLINE DERIVATIVE BRWD1, RB1, ARG2 CTSL 4237/4885MEN1 2153/4885KMT2A 558/4885
US-20110275827-A1 Mitotic Kinesin Inhibitor KIF15, KIF5A, KIF5B CTSL 4128/4885MEN1 3155/4885KMT2A 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.